Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | PPARA | Q07869 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.58 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | RARG | P13631 | 1/20 | 0.58 |
| ▸ | CNR1 | P21554 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.58 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7293157 | 0.88 | CYP1A2 (0.69) | CYP1A2PPARACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4177084 | 0.87 | CYP1A2 (0.63) | CYP1A2PPARACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7324339 | 0.86 | PPARG (0.54) | CYP1A2PPARAPPARGEPHX2MMP8 | |
| SCHEMBL10521821 | 0.84 | MMP8 (0.61) | CYP1A2PPARAPPARGEPHX2MMP8 | |
| SCHEMBL4611137 | 0.83 | CYP1A2 (0.59) | CYP1A2PPARACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL838961 | 0.83 | CYP1A2 (0.63) | CYP1A2PPARACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL838962 | 0.83 | CYP1A2 (0.63) | CYP1A2PPARACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6154521 | 0.83 | CYP1A2 (0.63) | CYP1A2PPARACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7325865 | 0.83 | CYP1A2 (0.56) | CYP1A2PPARACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7325869 | 0.83 | CYP1A2 (0.56) | CYP1A2PPARACYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| US-20030100548-A1 | Arylpiperazines and their use as metallaproteinase inhibiting agents (mmp) | ASTRAZENECA AB (SE) | 2003-05-29 | — | — | US | disclosed |
| CN-1404474-A | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2003-03-19 | — | — | CN | disclosed |
| EP-1274697-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| EP-1261595-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | AstraZeneca AB (SE) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001062751-A1 | ARYLPIPERAZINES AND ARYLPIPERIDINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| WO-2001062750-A1 | ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) | ASTRAZENECA AB (SE) | 2001-08-30 | — | — | WO | disclosed |
| US-4914129-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1990-04-03 | — | — | US | disclosed |
| US-4889869-A | ANTIALDOSTERONISM AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-12-26 | — | — | US | disclosed |
| US-4758584-A | Antihypertensive 5-amino-4-hydroxyvaleryl derivatives substituted by sulphur-containing groups | CIBA-GEIGY CORPORATION (US) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100548-A1 | Arylpiperazines and their use as metallaproteinase inhibiting agents (mmp) | MMP13, MMP3, MMP11 | CYP1A2 151/4885PPARA 2795/4885CYP3A4 542/4885 |
| US-20030139419-A1 | Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents | MMP13, MMP3, MMP2 | CYP1A2 70/4885PPARA 1926/4885CYP3A4 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.